Sanders Williams - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Dr. R. Sanders Williams, M.D., is an Independent Director of Amgen Inc. R. Sanders Williams is President of Gladstone Institutes, a nonprofit biomedical research enterprise, and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, both since 2010. He is also a Professor of Medicine at the University of California, San Francisco since 2010. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean of the DukeNUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center. Dr. Williams was a director of the Laboratory Corporationrationration of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit Committee and chairing the Quality and Compliance Committee. Dr. Williams was a director of BristolMyers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a nonprofit institution that is distinct from Gladstone Institutes, since 2012 and on the board of directors of Exploratorium, a nonprofit science museum and learning center located in San Francisco, since 2011. Dr. Williams was elected to the National Academy of Medicine in 2002
Age: 67  Director Since 2014      
805-447-1000  http://www.amgen.com
Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Alice SchwartzBio Rad Laboratories
1967
Alan GarberVertex Pharmaceuticals Incorpor
2017
Jeffrey EdwardsBio Rad Laboratories
2017
Jackson TaiEli Lilly and Company
2013
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Giovanni CaforioBristol Myers Squibb Company
2017
Thomas CechMerck Co
2009
Pamela CraigMerck Co
2015
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Peter McDonnellAllergan plc
2015
William SpenglerEndo International plc
2008
Patricia RussoMerck Co
1995
Ronald TaylorAllergan plc
2013
Karen HornEli Lilly and Company
2012
Jose BaselgaBristol Myers Squibb Company
2018
Michelle KumbierAbbott Laboratories
2018
Douglas IngramEndo International plc
2016
Melinda LitherlandBio Rad Laboratories
2017
Rochelle LazarusMerck Co
2004
Todd SisitskyEndo International plc
2016
Robert BertoliniBristol Myers Squibb Company
2017

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Did you try this?

Run Piotroski F Score Now
   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Piotroski F Score

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.